Expertise in
8
conditions

Daniel C. Cattran

Toronto, ON, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
8
conditions
Toronto, ON, CA 
OverviewLocationsClinical Research

Overview

Daniel Cattran practices in Toronto, Canada. Mr. Cattran is highly rated in 8 conditions, according to our data. His top areas of expertise are Glomerulonephritis, Membranous Nephropathy, IgA Nephropathy, Kidney Transplant, and Nephrectomy.

His clinical research consists of co-authoring 123 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Toronto, ON, Canada
Other Locations
Toronto, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy (ITN080AI)
Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy (ITN080AI)
Enrollment Status: Recruiting
Publish Date: September 26, 2025
Intervention Type: Drug
Study Drug: Belimumab
Study Phase: Phase 2
Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study Low Dose Study
Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study Low Dose Study
Enrollment Status: Completed
Publish Date: September 23, 2021
Intervention Type: Drug
Study Phase: Not Applicable
A Pilot Study to Assess the Efficacy of Rituximab Therapy in Patients With Treatment Resistant Idiopathic Focal Segmental Glomerulosclerosis (FSGS): Integrating an Assessment of the Relevance of suPAR and Activation of Podocyte β3 Integrin
A Pilot Study to Assess the Efficacy of Rituximab Therapy in Patients With Treatment Resistant Idiopathic Focal Segmental Glomerulosclerosis (FSGS): Integrating an Assessment of the Relevance of suPAR and Activation of Podocyte β3 Integrin
Enrollment Status: Completed
Publish Date: February 10, 2020
Intervention Type: Biological
Study Phase: Phase 2
Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects: The TRANSLATE Study
Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects: The TRANSLATE Study
Enrollment Status: Completed
Publish Date: January 16, 2018
Intervention Type: Drug
Study Phase: Phase 4
View 3 Less Clinical Trials

123 Total Publications

Erratum to "Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial Cohorts" [Kidney International Reports Volume 10, Issue 4, April 2025, Pages 1283-1287].
Erratum to "Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial Cohorts" [Kidney International Reports Volume 10, Issue 4, April 2025, Pages 1283-1287].
Journal: Kidney international reports
Published: July 18, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Cattran's expertise for a condition
ConditionClose
View All 10 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile